| Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force AB Hauber, JM González, CGM Groothuis-Oudshoorn, T Prior, ... Value in Health, 2016 | 1105 | 2016 |
| A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody A Chari, JG Berdeja, A Oriol, N Van De Donk, P Rodriguez, E Askari, ... Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood 136 …, 2020 | 64 | 2020 |
| Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)× CD3 bispecific antibody, in relapsed … JG Berdeja, AY Krishnan, A Oriol, NWCJ van de Donk, P Rodríguez-Otero, ... Journal of Clinical Oncology 39 (15_suppl), 8008-8008, 2021 | 32 | 2021 |
| Early phase clinical trials extension to guidelines for the content of statistical analysis plans V Homer, C Yap, S Bond, J Holmes, D Stocken, K Walker, EJ Robinson, ... bmj 376, 2022 | 25 | 2022 |
| A block slipping on a sphere with friction: Exact and perturbative solutions T Prior, EJ Mele American Journal of Physics 75 (5), 423-426, 2007 | 25 | 2007 |
| Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed/refractory multiple myeloma A Chari, P Hari, NJ Bahlis, MV Mateos, NWCJ van de Donk, B Dholaria, ... Blood 138, 161, 2021 | 24 | 2021 |
| A comparison of two experimental design approaches in applying conjoint analysis in patient-centered outcomes research: a randomized trial ET Kinter, TJ Prior, CI Carswell, JFP Bridges The Patient: Patient-Centered Outcomes Research 5, 279-294, 2012 | 20 | 2012 |
| Subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma: results from a phase 1b multicohort study P Rodriguez-Otero, B Dholaria, E Askari, DE Reece, NWCJ van de Donk, ... Blood 138, 1647, 2021 | 19 | 2021 |
| A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab … P Rodríguez-Otero, A D'Souza, DE Reece, NWCJ van de Donk, A Chari, ... Journal of Clinical Oncology 40 (16_suppl), 8032-8032, 2022 | 18 | 2022 |
| S183: novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1B results for talquetamab (a GPRC5D X CD3 bispecific antibody … NW Van de Donk, N Bahlis, MV Mateos, K Weisel, B Dholaria, AL Garfall, ... HemaSphere 6, 84-85, 2022 | 16 | 2022 |
| Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming–Harrington class of weights in oncology clinical trials TJ Prior Statistical methods in medical research 29 (12), 3525-3532, 2020 | 16 | 2020 |
| S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY‐BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS P Rodriguez Otero, A D'Souza, D Reece, NW van de Donk, A Chari, ... HemaSphere 6, 89-90, 2022 | 11 | 2022 |
| Comment on “A block slipping on a sphere with friction: Exact and perturbative solutions,” by Tom Prior and EJ Mele [Am. J. Phys. 75 (5), 423–426 (2007)] OL de Lange, J Pierrus, T Prior, EJ Mele American Journal of Physics 76 (1), 92-93, 2008 | 7 | 2008 |
| EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma O Landgren, TJ Prior, T Masterson, C Heuck, OF Bueno, AB Dash, ... Blood 144 (4), 359-367, 2024 | 6 | 2024 |
| S188: Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1B results PR Otero, A D’Souza, D Reece, NW van de Donk, A Chari, A Krishnan, ... HemaSphere 6, 89-90, 2022 | 4 | 2022 |
| B04: Combination of subcutaneous teclistamab with daratumumab in patients with relapsed/refractory multiple myeloma (RRMM): Results from a phase 1B multicohort study P Rodriguez-Otero, B Dholaria, E Askari, D Reece, N van de Donk, ... HemaSphere 6, 7-8, 2022 | 2 | 2022 |
| B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS M Mateos, P Hari, N Bahlis, A Chari, N van de Donk, B Dholaria, ... HemaSphere 6, 9, 2022 | 1 | 2022 |
| OAB-025: Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)× CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results … NWCJ Van De Donk, A Krishnan, A Oriol, JG Berdeja, P Rodríguez-Otero, ... Clinical Lymphoma Myeloma and Leukemia 21, S16-S17, 2021 | 1 | 2021 |
| Abstract CT236: A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis E Vilar-Sanchez, C Burke, MRC Correa, E Dekker, WM Grady, P Grandval, ... Cancer Research 80 (16_Supplement), CT236-CT236, 2020 | 1 | 2020 |
| OA-01 Talquetamab (tal)+ Daratumumab (dara)+ Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study NJ Bahlis, N van de Donk, D Reece, M Bhutani, B Dholaria, A D'Souza, ... Clinical Lymphoma Myeloma and Leukemia 24, S1, 2024 | | 2024 |
